{"task_id": "c74dfdd487fe1f71", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 171/464)", "text": "nvolved\nNotes\nDIAGNOSTIC ISSUES (CONT\u2019D)\nNotes\n159\n\n--- Page 181 ---\nApproach to Anticoagulation Therapies\nClass/Drugs\nMechanism\nIndications\nUsual dose\nComplications/\nmonitoring\nWarfarin\nInhibition of gamma\ncarboxylation by\ninhibition of the vitamin\nK dependent epoxide\nreductase. Inhibits\nhepatic synthesis of\nvitamin K dependent\nfactors (II, VII, IX, X,\nprotein S, protein C)\nDVT/PE\nAtrial fibrillation\nProsthetic\nvalves\nWarfarin 5 mg PO daily \u00033\ndays, then adjust based\non INR\nComplications\u2014bleeding\n(may be reversed with\nvitamin K), coumadin\ninduced skin necrosis\nMonitor\u2014INR\nUnfractionated\nheparin\nIndirect thrombin and\nfactor Xa inhibitor (non-\nselective). Binds to\nantithrombin (AT) and\nconverts it from a slow\nform to fast acting form,\nwhich binds and\ninactivates thrombin and\nfactors Xa, IXa, XIa, XIIa\nHeparin resistance is usually\ndue to AT deficiency and\ncould be treated with AT\nconcentrates\nAcute DVT/PE\nArterial\nembolism\nProsthetic\nvalves\nACS\nDVT prophylaxis\nFor acute clot,\nunfractionated heparin\n5000 U IV bolus, then\n1000 U/h, and adjust to\n1.5\u20132.5\u0003 normal PTT\nFor DVT prophylaxis,\nunfractionated heparin\n5000U SC 2 h before\nsurgery, then 5000U SC BID\nComplications\u2014bleeding\n(may be reversed by\nprotamine 1 mg/100 U\nUFH), HITT, osteoporosis\nMonitor\u2014aPTT (1.5\u20132.5\u0003\nnormal) and platelets\nNarrow therapeutic window\nand highly variable\ndose\u2013response curve\nLow molecular\nweight\nheparin:\nEnoxaparin\nDalteparin\nTinzaparin\nIndirect factor Xa inhibitor\n(relatively selective).\nBinds to AT and converts\nit from a slow form to fast\nacting form, which binds\nand inactivates factor Xa,\nand to a smaller extent,\nthrombin\nInactivation of thrombin\nspecifically requires\nheparin binding to both AT\nand thrombin. This\ncomplex only forms with\nheparin chains \u000618\nsaccharide long. Thus,\nLMWH is not as effective in\ninhibiting thrombin and\ndoes not prolong aPTT\nAcute DVT/PE\nMaintenance\nDVT/PE in\ncancer\npatients\nArterial\nembolism\nProsthetic\nvalves\nACS\nDVT prophylaxis\nFor acute clots, enoxaparin\n1 mg/kg SC BID or\n1.5 mg/kg SC daily,\ndalteparin 200 U/kg SC\ndaily, tinzaparin 175 U/kg\nSC daily\nFor DVT prophylaxis,\nenoxaparin 40 mg SC daily\n\u00037\u201314 days starting 12 h\npre op, dalteparin 2500U\nSC 1 h pre op, then 2500 U\nSC 6 h after, then 5000 U\nSC daily \u00035\u201314 days\nComplications\u2014bleeding\n(may be reversed partially\nwith protamine sulfate\n1 mg/100 anti Xa U of\nLMWH), HITT, avoid in\nspinal surgery\nMonitor\u2014anti factor Xa\nactivity and platelets.\nAnticoagulant response\ncorrelates well with body\nweight, allowing fixed\ndosing without\nmonitoring usually. Less\nlikely to induce HITT but\nstill requires platelet\nmonitoring\nHeparinoids:\nDanaparoid\n(organon)\nIndirect factor Xa\ninhibitors (selective).\nMixture of heparin sulfate,\ndermatan sulfate, and\nchondroitin sulfate. Inhibits\nthrombin via a\ncombination of AT (heparin\ncofactor I), heparin cofactor\nII, and some undefined\nmechanism\nMore selective factor Xa\ninhibitor than LMWH,\nwith a ratio of antifactor\nXa to AT activity of 28:1\ncompared to 3:1 with\nLMWH. aPTT not useful\nfor monitoring\nHITT\nAcute DVT\nFor HITT, danaparoid 2000\nanti factor Xa U IV bolus,\nthen 150\u2013200 U/h, titrate\nto plasma anti Xa level of\n0.5\u20130.8 U/mL\nComplications\u2014bleeding\nMonitor\u2014anti factor Xa\nactivity. Particularly\nimportant in renal failure\n10% cross reactivity\nbetween danaparoid and\nthe antibody responsible\nfor HITT, but clinical\nsignificance is uncertain\n160\nApproach to Anticoagulation Therapies", "text_length": 3420, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 171/464)", "type": "chunk", "chunk_index": 170, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.480986", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.481696", "status": "complete", "chunks_added": 2}